Please assess the completion status of the following clinical trial:

Trial Title: Effect of DLBS1033 After Primary PCI in Patients With STE-ACS

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
KEY Inclusion Criteria:~1. Signed informed consent.~2. Men or women of 30-75 years of age.~3. Evidence of acute ST elevation myocardial infarction (STEMI) at screening, as confirmed by ECG presentation of STEMI: new ST elevation at the J point in two contiguous leads with the cut-points: ≥ 0.1 mV in all leads other than leads V2-V3, where the following cut-points apply: ≥ 0.2 mV in men ≥ 40 years, ≥ 0.25 mV in men \< 40 years, or ≥ 0.15 mV in women; or new or presumably new left bundle-branch block (LBBB); and with at least one of the following:~   * Positive plasma biomarkers of myocardial necrosis (cardiac troponin I \[cTnI\]).~  * Possible ischaemic symptoms include various combinations of chest, upper extremity, mandibular or epigastric discomfort (with exertion or at rest) or an ischaemic equivalent such as dyspnoea or fatigue.~4. The onset of the STEMI is \> 3 hours before undergoing the primary PCI.~5. Therapy with study medication can be started within 24 hours after primary PCI.~6. Able to take oral medication.~KEY Exclusion Criteria:~1. Females of childbearing potential: pregnancy, breast-feeding.~2. History of hemorrhagic stroke, serious head injury within the last 3 months.~3. History of major surgery within the last 6 months.~4. History of PCI or CABG, or previous myocardial infarction.~5. Ongoing long term need for oral anticoagulants, antiplatelets, fibrinolytic, or antithrombotic agents, other than the study medication.~6. Having any implanted pacemaker or cardiac resynchronization therapy (CRT) or cardiac resynchronization therapy defibrillators (CRT-D).~7. Present with cardiogenic shock, 3rd degree atrioventricular (AV) block, complex anatomical coronary condition.~8. Planned for a staged PCI within 30 days after the current PCI~9. Inadequate liver function~10. CRUSADE bleeding score of \> 30~11. Known or suspected allergy to other lumbrokinase products.~12. Prior experience with DLBS1033 or other oral lumbrokinase products.~13. Clinical evidence of malignancies with survival period \< 1 year.~14. Any other disease state, including chronic or acute systemic infections, uncontrolled illnesses or other chronic diseases, which judged by the investigator, could jeopardize patient's safety or interfere with trial participation or trial evaluation.~15. Subjects enrolled in other interventional protocol within 30 days prior to Screening~16. Any other disease state, including chronic or acute systemic infections, uncontrolled illnesses or other chronic diseases, which judged by the investigator, could jeopardize patient's safety or interfere with trial participation or trial evaluation.

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- DLBS1033 (Type: EXPERIMENTAL): DLBS1033 enteric-coated tablet is administered at the dose of 980 mg (two tablets@490 mg) three times daily, everyday for four weeks of study period
- Placebo (Type: PLACEBO_COMPARATOR): Placebo is administered two tablets three times daily, everyday for four weeks of study period

Based on this trial design, predict the completion outcome and termination type (if applicable).